Table 3.

Summary of incidence of AEs and ADRs

n (%)	All patients (N = 5578)
Any AEs	4662 (83.6)
Any ADRs	3767 (67.5)
Serious AEs	2246 (40.3)
Serious ADRs	597 (10.7)
AEs leading to dose reduction of nintedanib	1242 (22.3)
ADRs leading to dose reduction of nintedanib	1196 (21.4)
AEs leading to discontinuation of nintedanib	2276 (40.8)
ADRs leading to discontinuation of nintedanib	1356 (24.3)
AEs leading to death	1107 (19.8)
ADRs leading to death	140 (2.5)

AE adverse event, ADR adverse drug reaction